Garnet Health Medical Center

Summary

Garnet Health Medical Center is a medical facility located in Middletown, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Kidney Cancer and other specialties. Garnet Health Medical Center is involved with conducting 91 clinical trials across 149 conditions. There are 1 research doctors associated with this hospital, such as Jeffrey M. Stewart.

Top PIs

Clinical Trials running at Garnet Health Medical Center

Prostate Cancer

Non-Small Cell Lung Cancer

Laryngeal Cancer

Oropharyngeal Carcinoma

Prostate Adenocarcinoma

Colon Cancer

Throat Cancer

Lip and Oral Cavity Cancer

Oral Cancers

Breast Cancer

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

Recruiting

2 awards

Phase 3

Carboplatin Before Surgery

for Prostate Cancer

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with high-risk prostate cancer with BRCA1 and BRCA2 gene mutations.

Recruiting

1 award

Phase 2

10 criteria